Novartis Blocks Sun’s Nilotinib Plans In India

Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the anticancer while the originator's patent stands valid.